This site is intended for a global audience
Contact Us

Science Stories

featured story

Scientific advances are reshaping how small cell lung cancer is understood and treated. As interest grows in first-line maintenance strategies, researchers are exploring new ways to extend the impact of initial therapy in this historically difficult-to-treat cancer.

While the oncology community is large, Jazz focuses on smaller groups of people facing unique challenges and difficult odds, such as those living with small cell lung cancer (SCLC). In the U.S., approximately 13 percent of lung cancers are small cell and nearly 30,000 new cases of SCLC are recorded in the U.S. every year.
 

There were approximately 17-18 million new cancer cases diagnosed worldwide in 2018, of which about 7% – or 1.2 million people – were blood cancers. While tremendous progress in the treatment of these cancers has been made and survival rates for common blood cancers have consistently improved over time, there is still work to be done. Certain blood cancers, like acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL), can be more difficult to treat because they are rare and have a more aggressive nature.

Every three minutes, someone in the U.S. is diagnosed with a blood cancer.  Fast-growing blood cancers like acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) can become life-threatening if left untreated because they can quickly spread to other parts of the body, including the brain and spinal cord.  Hematopoietic stem cell transplantation (HSCT) can provide an important option in improving outcomes for appropriate patients.